Mining Druggable Sites in Influenza A Hemagglutinin: Binding of the Pinanamine-Based Inhibitor M090
- PMID: 39811135
- PMCID: PMC11726360
- DOI: 10.1021/acsmedchemlett.4c00502
Mining Druggable Sites in Influenza A Hemagglutinin: Binding of the Pinanamine-Based Inhibitor M090
Abstract
Assessing the binding mode of drug-like compounds is key in structure-based drug design. However, this may be challenged by factors such as the structural flexibility of the target protein. In this case, state-of-the-art computational methods can be valuable to explore the linkages between structural and pharmacological data. Following this strategy, extended molecular dynamics simulations and thermodynamic integration calculations are used to examine the binding of the potent antiviral inhibitor M090 and related pinanamine-based analogues, covering a 250-fold difference in inhibitory potency to the influenza A hemagglutinin, which is essential for virus entry and membrane fusion. This analysis has disclosed the hydrophobic shielding effect played by the 3-cyclopropylthiophene moiety in M090. Furthermore, the results support the negative effect of the resistance-induced E742 → D mutation, which should weaken the binding by increasing the structural flexibility of the L2-BS loop. The results pave the way to exploration of the antiviral activity of novel compounds.
© 2024 The Authors. Published by American Chemical Society.
Conflict of interest statement
The authors declare no competing financial interest.
Figures






Similar articles
-
Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.J Med Chem. 2018 Jun 28;61(12):5187-5198. doi: 10.1021/acs.jmedchem.8b00042. Epub 2018 Jun 11. J Med Chem. 2018. PMID: 29799746 Free PMC article.
-
Design and synthesis of pinane oxime derivatives as novel anti-influenza agents.Bioorg Chem. 2020 Sep;102:104106. doi: 10.1016/j.bioorg.2020.104106. Epub 2020 Jul 17. Bioorg Chem. 2020. PMID: 32739481
-
N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.Eur J Med Chem. 2020 May 15;194:112223. doi: 10.1016/j.ejmech.2020.112223. Epub 2020 Mar 13. Eur J Med Chem. 2020. PMID: 32220685
-
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors.Expert Opin Pharmacother. 2021 Apr;22(6):715-728. doi: 10.1080/14656566.2020.1856814. Epub 2020 Dec 24. Expert Opin Pharmacother. 2021. PMID: 33327812 Review.
-
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.Annu Rev Biochem. 2000;69:531-69. doi: 10.1146/annurev.biochem.69.1.531. Annu Rev Biochem. 2000. PMID: 10966468 Review.
References
-
- Cozzini P.; Kellogg G. E.; Spyrakis F.; Abraham D. J.; Costantino G.; Emerson A.; Fanelli F.; Gohlke H.; Kuhn L. A.; Morris G. M.; Orozco M.; Pertinhez T. A.; Rizzi M.; Sotriffer C. A. Target flexibility: An emerging consideration in drug discovery and design. J. Med. Chem. 2008, 51, 6237–6255. 10.1021/jm800562d. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources